Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2000

View Archived Issues

Antigenics and Aquila complete merger

Photogen Technologies' PH-10 shows promise for PDT in preclinical studies

Val-HeFT results reported at AHA sessions

XTL Biopharmaceuticals and Pharming to codevelop lactoferrin for HCV treatment

Company Profile: Vasogen

FDA approves Lovenox for seventh indication

Ligand's Targretin recommended for approval by CPMP

Inspire updates product developments during BIO-Europe

First clinical trial results with Oxford Biomedica's MetXia reported

Lipitor reduces ischemic events following ACS

Phase III results reported for Natrecor in CHF

COPERNICUS results show good efficacy for carvedilol in severe HF

Novel nucleoside transport inhibitors may overcome limitations of dipyridamole

Nonanticoagulant heparin derivative designed to exert antiangiogenic activity

No consistent PKC inhibition or significant MDR reversal in melanoma patients treated with CGP-41251

Penwest and Celltech complete phase Ia trials with lead pain management candidate

NCI-EORTC-AACR highlights: E-7070 progresses to phase II based on phase I findings

Small-molecule JNK inhibitor suppresses joint destruction in rat adjuvant arthritis model

Evidence of biological and clinical activity emerges from phase I/II trial of AnergiX.RA

Triple TCR peptide vaccine for MS enters phase I/II trial

Novel nontaxane tubulin-polymerizing epothilone lactam discovered at BMS

Mesopram, a specific PDE4 inhibitor: evidence supports clinical development for MS

Pollinosis-associated genes discovered in Japan

New series of thymidylate synthase inhibitors designed at Sunesis

Santen presents novel urea TNF-alpha production inhibitors

New compounds synthesized at Pfizer act as inhibitors of protein farnesyltransferase

Selective GABA-A receptor subunit ligands discovered at Merck

Potent new anti-HIV agents acting on viral protease disclosed in recent patent

Sulfonamide-based MMP inhibitors in development at Shionogi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...